These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 7240375)
1. Daughters of women with breast cancer have elevated mean 24-hour prolactin (PRL) levels and a partial resistance of PRL to dopamine suppression. Levin PA; Malarkey WB J Clin Endocrinol Metab; 1981 Jul; 53(1):179-83. PubMed ID: 7240375 [No Abstract] [Full Text] [Related]
2. Twenty four-hour prolactin profiles and prolactin responses to dopamine in long distance running women. Chang FE; Richards SR; Kim MH; Malarkey WB J Clin Endocrinol Metab; 1984 Oct; 59(4):631-5. PubMed ID: 6480800 [TBL] [Abstract][Full Text] [Related]
3. Different rebound rise in plasma prolactin during the postdopamine infusion phase in puerperal women and patients with pathological hyperprolactinemia. Genazzani AR; Cavagnini F; Picotti GB; Ghigo E; De Leo V; Galva MD; Maraschini C; Muller EE J Clin Endocrinol Metab; 1983 Dec; 57(6):1159-63. PubMed ID: 6630411 [TBL] [Abstract][Full Text] [Related]
4. Thyroid-stimulating hormone and prolactin levels in breast cancer. Aldinger KA; Schultz PN; Blumenschein GR; Samaan NA Arch Intern Med; 1978 Nov; 138(11):1638-41. PubMed ID: 102267 [TBL] [Abstract][Full Text] [Related]
5. Differential effects of a low dose dopamine infusion on prolactin secretion in normal and hyperprolactinemic subjects. Serri O; Kuchel O; Buu NT; Somma M J Clin Endocrinol Metab; 1983 Feb; 56(2):255-9. PubMed ID: 6822635 [TBL] [Abstract][Full Text] [Related]
6. The effects of ovariectomy and estrogen treatment on the dopamine inhibition of gonadotropin and prolactin release. Judd SJ; Rigg LA; Yen SS J Clin Endocrinol Metab; 1979 Aug; 49(2):182-4. PubMed ID: 572372 [TBL] [Abstract][Full Text] [Related]
7. Prolactin serum level in patients with breast cancer. Cohen AD; Cohen Y; Maislos M; Buskila D Isr Med Assoc J; 2000 Apr; 2(4):287-9. PubMed ID: 10804904 [TBL] [Abstract][Full Text] [Related]
8. Failure of dopamine infusion to suppress the plasma prolactin response to sulpiride in normal and hyperprolactinemic subjects. Crosignani PG; Reschini E; Peracchi M; Lombroso GC; Mattei A; Caccamo A J Clin Endocrinol Metab; 1977 Oct; 45(4):841-4. PubMed ID: 410826 [TBL] [Abstract][Full Text] [Related]
9. Disordered nocturnal prolactin regulation in women with breast cancer. Malarkey WB; Schroeder LL; Stevens VC; James AG; Lanese RR Cancer Res; 1977 Dec; 37(12):4650-4. PubMed ID: 922745 [TBL] [Abstract][Full Text] [Related]
10. [Circadian rhythm of prolactin in patients with chronic renal failure]. Riemel A; Grzeszczak W; Koziak H Przegl Lek; 1995; 52(9):440-4. PubMed ID: 8834645 [TBL] [Abstract][Full Text] [Related]
11. Prolactin response to dopamine and valproate administration in breast cancer patients. Stalldecker GB; Pigni J; Fuentes AM; Vegh I Biomed Pharmacother; 1989; 43(4):301-6. PubMed ID: 2506942 [TBL] [Abstract][Full Text] [Related]
12. Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture. Malarkey WB; Kennedy M; Allred LE; Milo G J Clin Endocrinol Metab; 1983 Apr; 56(4):673-7. PubMed ID: 6833457 [TBL] [Abstract][Full Text] [Related]
13. Pulsatile prolactin secretion in hyperprolactinemia due to presumed pituitary stalk interruption. Samuels MH; Henry P; Kleinschmidt-Demasters B; Lillehei K; Ridgway EC J Clin Endocrinol Metab; 1991 Dec; 73(6):1289-93. PubMed ID: 1955511 [TBL] [Abstract][Full Text] [Related]
14. Circadian variation of basal plasma prolactin, prolactin response to suckling, and length of amenorrhea in nursing women. Díaz S; Serón-Ferré M; Cárdenas H; Schiappacasse V; Brandeis A; Croxatto HB J Clin Endocrinol Metab; 1989 May; 68(5):946-55. PubMed ID: 2715293 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer. Lissoni P; Vaghi M; Ardizzoia A; Fumagalli E; Tancini G; Gardani G; Conti A; Maestroni GJ Neuro Endocrinol Lett; 2001; 22(1):27-9. PubMed ID: 11335876 [TBL] [Abstract][Full Text] [Related]
16. Mammary cancer risk: circulating TSH and prolactin, fibrocystic breast disease in chronoepidemiologic perspective. Tarquini B; Benvenuti M; Legnaioli M; Bazzani M; Cagnoni M; Halberg F Cancer Detect Prev; 1981; 4(1-4):525-34. PubMed ID: 7349819 [TBL] [Abstract][Full Text] [Related]
17. Possible linkage between the ability to change the period (tau) of the prolactin and cortisol rhythms in women and breast cancer risk. Lewy H; Haus E; Ashkenazi IE Chronobiol Int; 2007; 24(2):365-81. PubMed ID: 17453854 [TBL] [Abstract][Full Text] [Related]
18. Circadian variation of serum prolactin and TSH of women in health or with mammary carcinoma, fibroadenoma or fibrocystic mastopathy. Tarquini B; Gheri R; Romano S; Costa A; Cagnoni M; Lee JK; Halberg F Int J Chronobiol; 1980; 7(2):101-15. PubMed ID: 7450919 [TBL] [Abstract][Full Text] [Related]
19. Elevated serum levels of estrogen and prolactin in daughters of patients with breast cancer. Henderson BR; Gerkins V; Rosario I; Casagrande J; Pike MC N Engl J Med; 1975 Oct; 293(16):790-5. PubMed ID: 1160970 [TBL] [Abstract][Full Text] [Related]
20. HER2 expression in breast cancer: correlation with endocrine function and psychological status in operable and metastatic breast cancer. Lissoni P; Messina G; Rovelli F; Brivio F; Fumagalli L; Villa S; Bartolacelli E In Vivo; 2009; 23(6):987-9. PubMed ID: 20023245 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]